Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jan 31, 2022 11:09am
160 Views
Post# 34378571

RE:RE:RE:RE:MDGL Update

RE:RE:RE:RE:MDGL UpdateWhat are the chances that little TH could acquire the capability to formulate a successful PDC with siRNA as the payload? They were able to put together TH-1902 rather inexpensively. Does it get exponentially harder from this point forward?

jfm1330 wrote: Again, they would not search a siRNA apecialist if they would see nothing on the efficacy side leading to a proof of concept. Making a PDC that would work linking SiRNA to TH19P01 is another ball game than doing it with a rather small, stable and old proven drug like docetaxel.

Wino115 wrote: What the NASH space needs to see -- a successful leader moving to approvall.  I think this was the companion NAFLD trial to the main MAESTRO trial they're doing on NASH, but it is also supposed to finish by mid year.  Any good news in NASH will help to rebuild sentiment that it's a therapy worth going for.

For THTX news Muslix, from what tidbits came out in the presentations and subsequent discussions is that they are still moving up the dosage. Means they may still have to keep going to find DLTs, then back down one level and test six patients at that.  Then we have MTD.  I think my "ready-reckoner" was if its the 320mg (1.5x taxel SOC) it would have been finished Jan, 400-ish level would be Feb, 500-ish level would be Mar.  If it keeps going up to the 700-ish level, maybe even beyond Mar.  So looks like we're at least past the 400 level, so Feb at best and maybe Mar.  WHile it's painful to wait, this waiting does actually have financial implications if you believe the higher the does, the higher the probabilitiy of something special in efficacy.

Be patient, it's a wait around good news, not bad.

muslix1 wrote:
one day it's going to be our turn pop up 20%...
but not today there's no news at 7.30 well see you tomorrow at 7.30 for news i hope

 




<< Previous
Bullboard Posts
Next >>